Growth Metrics

Lucid Diagnostics (LUCD) Shares Outstanding (Diluted Average) (2022 - 2025)

Lucid Diagnostics (LUCD) has disclosed Shares Outstanding (Diluted Average) for 4 consecutive years, with $92.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Diluted Average) rose 82.89% year-over-year to $92.1 million, compared with a TTM value of $92.1 million through Sep 2025, up 82.89%, and an annual FY2024 reading of $50.5 million, up 20.98% over the prior year.
  • Shares Outstanding (Diluted Average) was $92.1 million for Q3 2025 at Lucid Diagnostics, down from $99.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $99.0 million in Q2 2025 and bottomed at $35.8 million in Q2 2022.
  • Average Shares Outstanding (Diluted Average) over 4 years is $51.9 million, with a median of $43.4 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) grew 9.87% in 2024, then skyrocketed 112.36% in 2025.
  • Year by year, Shares Outstanding (Diluted Average) stood at $36.2 million in 2022, then grew by 15.44% to $41.8 million in 2023, then increased by 20.98% to $50.5 million in 2024, then soared by 82.38% to $92.1 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for LUCD at $92.1 million in Q3 2025, $99.0 million in Q2 2025, and $68.8 million in Q1 2025.